# Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation

> **NCT03836833** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Drugs for Neglected Diseases** · enrollment: 50 (estimated)

## Conditions studied

- HIV

## Interventions

- **DRUG:** ABC/3TC/LPV/r granules (30/15/40/10 mgs)
- **DRUG:** LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)

## Key facts

- **NCT ID:** NCT03836833
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-04
- **Primary completion:** 2019-11
- **Final completion:** 2019-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-06-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836833, "Lopinavir/r/ Lamivudine/ Abacavir as an Easy to Use Paediatric Formulation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03836833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*